Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00748553 · ClinicalTrials.gov registry record · Phase 1
A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer
A Phase 1 study, sponsored by University of Utah.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00748553 is a Phase 1 study that has completed, run by University of Utah. The registered enrollment target is 30 participants.
The verdict
NCT00748553, a Phase 1 study, has completed, sponsored by University of Utah.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to test whether treatment of patients with advanced or metastatic solid tumors or breast cancer with Abraxane plus Vidaza is safe and results in good tumor response. All patients enrolling in this study will receive treatment with Abraxane and Vidaza. Safety will be assessed by adverse events, laboratory results and performance status. Tumor response will be measured by RECIST criteria.
Interventions
- DRUG Azacitidine (Vidaza)
- DRUG Nab-paclitaxel (Abraxane)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2008-09 |
| Est. Completion | 2015-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00748553
The ClinicalTrials.gov registry entry for NCT00748553 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Azacitidine (Vidaza) is the first listed.
NCT00748553 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00748553 about?
NCT00748553 is a clinical study titled "A Phase I/II Clinical Trial of Vidaza With Abraxane in Patients With Advanced/Metastatic Solid Tumors and Breast Cancer". The purpose of this clinical trial is to test whether treatment of patients with advanced or metastatic solid tumors or breast cancer with Abraxane plus Vidaza is safe and results in good tumor response. All patients enrolling in this study will receive treatment with Abraxane and Vidaza. Safety wil...
What is the current status of trial NCT00748553?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2008-09. Estimated completion is 2015-10.
What interventions are being tested in trial NCT00748553?
The interventions under investigation include: Azacitidine (Vidaza) (DRUG), Nab-paclitaxel (Abraxane) (DRUG).
Who is sponsoring clinical trial NCT00748553?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.